VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2020 | CONTESSA: tesataxel in HR+ breast cancer

Sara M. Tolaney, MD, MPH, Dana-Farber Cancer Institute, Boston, MA, discusses the results of the CONTESSA study (NCT03326674), a multicenter, randomized Phase III study of tesetaxel in patients with HER2-negative, HR-positive, locally advanced or metastatic breast cancer, previously treated with a taxane in the neoadjuvant setting. Tesetaxel was compared with capecitabine in this patient population and the combination approach demonstrated improved outcomes for the enrolled patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Dr. Tolaney has served in a consulting or advisory role for AstraZeneca, Lilly, Merck, Nektar, Novartis, Pfizer, Genentech/Roche, Immunomedics, Exelixis, Bristol-Myers Squibb, Eisai, Nanostring, Puma, Cyclacel, Sanofi, Celldex, Odonate, Seattle Genetics, Daiichi Sankyo, Silverback Therapeutics, G1 Therapeutics, Abbvie, Athenex, OncoPep, Kyowa Kirin Pharmaceuticals, Samsung Bioepsis Inc., CytomX, Gilead, Certara, Mersana Therapeutics.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter